Inloggad som:
avslutad_Commands, ACE-536-MDS-002
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
avslutad_Commands, ACE-536-MDS-002
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodyplastic Syndroms (MDS) in ESA Naive Subjects who require Red Blood Cell Transfusions.
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodyplastic Syndroms (MDS) in ESA Naive Subjects who require Red Blood Cell Transfusions.
Karolinska Universitetssjukhuset / Hematologisk vård
Mer information om studien för vårdgivare
Behandling
Ej tillämpbar
Ej tillämpbar
1st Line
Företag
Studien ändrades senast: (2025-05-05)